Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Voyager Therapeutics

- PMLiVE

Novartis revives delayed Singapore biotech plans

Aims to have biotechnology facility up and running before 2017

Novartis building

France, Germany and Spain join list of countries banning Novartis vaccines

Flu vaccines Agrippal and Fluad withdrawn after some batches found to be contaminated

Novartis building

NICE backs Novartis’ Tobi Podhaler in cystic fibrosis

But draft guidance doesn't recommend Forest’s Colobreathe

Europe set to approve first Glivec generic

CHMP backs Teva version of Novartis' blockbuster cancer drug

Novartis building

Gilenya cuts early relapse, brain loss in MS patients

Boosts prospects for oral drug as competitors emerge

- PMLiVE

Novartis launches YouTube cancer talk show

Each Voice Counts forms part of firm’s existing advanced breast cancer initiative

- PMLiVE

NICE in U-turn on Novartis’ Lucentis in diabetic macular oedema

Patient access scheme influences draft recommendation

- PMLiVE

Ruder Finn launches a social media meningitis campaign

The awareness campaign involves collaboration with three UK meningitis charities

Novartis’ COPD drug Seebri cleared in EU and Japan

Used with Breezhaler device in Europe and inhalation capsule in Japan

Novartis’ Peter Maag appointed president and CEO of XDx

Joins following launch of AlloMap test for transplant patients

Novartis drug effective in hard-to-treat psoriasis

Secukinumab to commence phase III trials

Novartis building

Novartis heart failure candidate clears phase III trial

Serelaxin proves effective in reducing all-cause mortality

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links